Wanbang Biopharmaceuticals

Founded in 1981, Wanbang Biopharmaceuticals (Wanbang Biopharma) is a global innovation-driven pharmaceutical company deep-rooted in China, and is a core member enterprise of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”, stock code: 600196-SH, 02196-HK).

Our business covers the whole healthcare industry chain including R&D, manufacturing, wholesale, distribution, chain stores, and internet sales. Currently Wanbang Biopharma holds and controls 20 subsidiaries and has established 7 manufacturing sites across China. In the past decade, Wanbang maintained a CAGR 22.85% in sales revenue, which exceeded 7.9 billion RMB (1.2 billion USD) in 2022.

Wanbang Biopharma actively improve the quality system to international level. At present, more than 10 production lines have passed site inspection by overseas health authority and obtained certification, among which, one sterile injectable production line has passed the EU and US FDA site inspection, and one oral solid preparation production line has passed the US FDA site inspection.